Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Research & Discovery › Genetic Research › Endocrine Therapy-Resistant Breast Cancers With Kinase Fusions May Benefit From Targeted Drugs

Endocrine Therapy-Resistant Breast Cancers With Kinase Fusions May Benefit From Targeted Drugs

May 14, 2020
|
staff reporter

NEW YORK – Based on the results of a study published in the Annals of Oncology in April, researchers suggested that testing metastatic breast cancer patients for kinase fusions, particularly those who become resistant to endocrine therapy, may identify targetable biomarkers and open up additional treatment opportunities.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
22
Featured Webinar

Trends in Variant Interpretation Workflows: Expert Insights to Advance NGS Oncology Profiling

Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

What's Popular?

In Cancer

  1. FDA Approves Daiichi Sankyo, AstraZeneca's Enhertu for Gastric, Gastroesophageal Junction Cancer

  2. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  3. Natera Sues Inivata, Alleging Infringement of Cancer Testing Patents

  4. Daiichi Sankyo, AstraZeneca's Enhertu Approved in EU for HER2-Positive Breast Cancer

  5. Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.